HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A sensitive luminescent assay for the histone methyltransferase NSD1 and other SAM-dependent enzymes.

Abstract
A major focus of our pediatric cancer research is the discovery of chemical probes to further our understanding of the biology of leukemia harboring fusion proteins arising from chromosomal rearrangements, and to develop novel specifically targeted therapies. The NUP98-NSD1 fusion protein occurs in a highly aggressive subtype of acute myeloid leukemia after rearrangement of the genes NUP98 and NSD1. The methyltransferase activity of NSD1 is retained in the fusion, and it gives rise to abnormally high levels of methylation at lysine 36 on histone 3, enforcing oncogene activation. Therefore, inhibition of the methyltransferase activity of NUP98-NSD1 may be considered a viable therapeutic strategy. Here, we report the development and validation of a highly sensitive and robust luminescence-based assay for NSD1 and other methyltransferases that use S-adenosylmethionine (SAM) as a methyl donor. The assay quantifies S-adenosylhomocysteine (SAH), which is produced during methyl transfer from SAM. SAH is converted enzymatically to adenosine monophosphate (AMP); in the process, adenosine triphosphate (ATP) is consumed and the amount of ATP remaining is measured using a luminescent assay kit. The assay was validated by pilot high-throughput screening (HTS), dose-response confirmation of hits, and elimination of artifacts through counterscreening against SAH detection in the absence of NSD1. The known methyltransferase inhibitor suramin was identified, and profiled for selectivity against the histone methyltransferases EZH2, SETD7, and PRMT1. HTS using the luminescent NSD1 assay described here has the potential to deliver selective NSD1 inhibitors that may serve as leads in the development of targeted therapies for NUP98-NSD1-driven leukemias.
AuthorsKatherine M Drake, Venita G Watson, Anne Kisielewski, Rebecca Glynn, Andrew D Napper
JournalAssay and drug development technologies (Assay Drug Dev Technol) Vol. 12 Issue 5 Pg. 258-71 (Jun 2014) ISSN: 1557-8127 [Electronic] United States
PMID24927133 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Validation Study)
Chemical References
  • Enzyme Inhibitors
  • Intracellular Signaling Peptides and Proteins
  • Nuclear Proteins
  • S-Adenosylmethionine
  • Histone Methyltransferases
  • Methyltransferases
  • Histone-Lysine N-Methyltransferase
  • NSD1 protein, human
Topics
  • Dose-Response Relationship, Drug
  • Enzyme Assays (methods)
  • Enzyme Inhibitors (analysis, chemistry, pharmacology)
  • High-Throughput Screening Assays
  • Histone Methyltransferases
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Intracellular Signaling Peptides and Proteins (antagonists & inhibitors, metabolism)
  • Luminescent Measurements (methods)
  • Methyltransferases (antagonists & inhibitors, metabolism)
  • Nuclear Proteins (antagonists & inhibitors, metabolism)
  • S-Adenosylmethionine (metabolism)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: